$PFE

Buckley Mortimer J purchased $960K of PFE

Buckley Mortimer J purchased 37,632 shares of PFIZER INC (PFE) at $25.52 ($0.96M total) on 2026-08-05.

Original reporting
SEC EDGAR · Buckley Mortimer J
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

A director open-market purchase is incremental sentiment information, not a new fundamental driver.

02

Market read

Traders may note the insider buy, but there is no accompanying guidance, legal, regulatory, or operational update.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is meaningful versus prior activity.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, after-hours/late session disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Pfizer Inc.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer director Buckley Mortimer J bought 37,632 shares in an open-market transaction on 2026-08-05 for about $960K.

Expected impact

Likely limited near-term impact; may modestly support sentiment but is usually not trade-driving alone.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, yet the filing provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity without broader industry news.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • Buckley Mortimer J

    Director who purchased 37,632 shares on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGNXMedAI 8/10

FDA Should Demand Proof, Not Just Protein, for Duchenne

The FDA is scrutinizing REGENXBIO's RGX-202 and Solid Biosciences' SGT-003, both Duchenne muscular dystrophy treatments, for accelerated approval. The FDA requires evidence that microdystrophin expression predicts clinical benefit, citing Pfizer's failed CIFFREO trial as a cautionary example. REGENXBIO reported 93% of patients reached 10% microdystrophin expression, but functional data is limited. The FDA seeks robust evidence before approval, given the permanent nature of gene therapy.

$NVOMed

Weight-loss drug developers line up to tap lucrative market

The weight-loss drug market is growing rapidly, with analysts projecting $100B in annual sales in the next decade. Novo Nordisk and Eli Lilly lead the sector, but other companies like Pfizer, Viking Therapeutics, and AstraZeneca are developing new treatments. Key drugs include Novo's amycretin and CagriSema, Pfizer's PF-3944, and Lilly's retatrutide, with varying degrees of success in clinical trials.

$PFELow

Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures wi

Public Citizen disclosed 'Most Favored Nation' drug pricing agreements between the U.S. government and Pfizer (PFE), Eli Lilly (LLY), and Novo Nordisk (NVO), warning of potential global price impacts. The nonprofit raised concerns about ambiguous provisions and missing details in the deals, questioning Trump's drug policy achievements. Pfizer and Lilly shares were down in premarket trading, according to Benzinga Pro.

$PFEMedAI 8/10

RSV Vaccines Are Highly Effective in Older Adults

Studies show RSV vaccines from GlaxoSmithKline and Pfizer are highly effective in older adults, mirroring clinical trial results. The vaccines performed similarly, and their efficacy remained high even after adjusting for healthcare access. Researchers are now studying the need for booster shots.